



	Extremely satisfied	Moderately satisfied	Neither satisfied nor dissatisfied	Moderately dissatisfied	Extremely dissatisfied	Not applicable
12. That the agency kept offerors informed about any delays in the solicitation process (considering both the initial release and any subsequent delays), if applicable? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
13. That the solicitation included clear submission instructions that sufficiently guided offerors or respondents in preparing offers or responses to requests for information? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
14. That the solicitation included clear submission instructions that sufficiently guided offerors or respondents in preparing offers or responses to requests for information? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
15. That the Government chose an appropriate contract type based on the requirement and associated risks? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
16. That the Government chose an appropriate source selection methodology? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
17. That the agency answered questions regarding the solicitation in such a way that it helped you to prepare the offer? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
18. With the opportunity to propose unique and innovative solutions (e.g., the solicitation and evaluation criteria promoted innovation)? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
19. With the amount of time the agency gave to submit an offer? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
20. That the solicitation's evaluation methodology allowed for the best selection among competing offers? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
21. With the quality of the agency's debriefing (e.g., it allowed you to understand how to improve on similar efforts in the future)? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<i>Overall Satisfaction</i> 22. How satisfied were you with your overall experience on this acquisition? .....	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
	Strongly agree	Agree	Neutral	Disagree	Strongly disagree	Not applicable
23. This transaction increased my confidence in the acquisition process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
24. If given the opportunity, what would you change about the process to improve your experience? [Open Text Field]						

The purpose of the Acquisition 360 Survey is to standardize the gathering of feedback regarding preaward and debriefing actions so that agencies can continually consider and improve their performance in early vendor engagement efforts and internal acquisition practices.

**C. Common Form**

This information collection is a common form. The General Services Administration is the sponsor agency of this common form. All executive agencies covered by the FAR will use this common form. Each executive agency will report their agency burden separately, and the reported information will be available at *Reginfo.gov*.

**D. Annual Burden**

*General Services Administration*

*Respondents:* 2,689.  
*Total Annual Responses:* 2,689.  
*Total Burden Hours:* 448.

**E. Public Comment**

A 60-day notice was published as a part of the notice of the proposed rulemaking for FAR case 2017-014 in the **Federal Register** at 85 FR 57177, on August 15, 2020. A respondent provided comments on a variety of issues on the proposed rule; one of the comments expressed support for this collection of information.

*Comment:* Regarding whether the collection of information will have

practical utility, the commenter stated that if better communication aids in the proper performance of FAR functions, both the information and the initiative to promote voluntary feedback has merit. The commenter finds this collection to be a worthy time investment to facilitate effective communication that could prevent delays or errors due to miscommunication.

*Response:* Noted.

*Obtaining Copies:* Requesters may obtain a copy of the information collection documents from the GSA Regulatory Secretariat Division, by calling 202-501-4755 or emailing *GSARegSec@gsa.gov*. Please cite OMB Control No. 9000-0204, Acquisition 360 Voluntary Survey.

**Janet Fry,**

*Director, Federal Acquisition Policy Division, Office of Governmentwide Acquisition Policy, Office of Acquisition Policy, Office of Governmentwide Policy.*

[FR Doc. 2023-18005 Filed 8-21-23; 8:45 am]

**BILLING CODE 6820-EP-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2023-N-3268]

**Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; establishment of a public docket; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

**DATES:** The meeting will be held on October 5, 2023, from 9:30 a.m. to 3 p.m. Eastern Time.

**ADDRESSES:** All meeting participants will be heard, viewed, captioned, and recorded for this advisory committee meeting via an online teleconferencing and/or video conferencing platform.

Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: <https://www.fda.gov/>